MedTrace Logo

Efficacy and Safety of the YUKON Drug Eluting Stent in Diffuse Coronary Artery Disease

NCT01418794 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 606

Last updated 2011-08-17

No results posted yet for this study

Summary

Polymer carried by drug-eluting stents may increase inflammatory response and thrombosis. Our previous study showed that polymer-free rapamycin-coated stents brings dose-dependent reduction in restenosis. This prospective, multicenter, randomized controlled clinical trials aimed to explore efficacy and safety of the YUKON drug eluting stent in diffuse coronary artery disease.

Conditions

  • Acute Coronary Syndromes

Interventions

DEVICE

High dose rapamycin stent

Concentration of rapamycin is 2.5%

DEVICE

Low dose rapamycin stent

Concentration of rapamycin is 1.5%

Sponsors & Collaborators

  • Shenyang Northern Hospital

    lead OTHER

Principal Investigators

  • Ya-Ling Han, MD · Shenyang Northern Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-10-31
Primary Completion
2011-11-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01418794 on ClinicalTrials.gov